Sarcoidosis-associated fatigue

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 255-263

  Drent, Marjolein ^a,b   Lower, Elyse E ^d,e   De Vries, Jolanda ^c  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e Oncology Hematology Care Inc   (United States)

Author keywords

Fatigue; Fatigue assessment scale; Quality of life; Sarcoidosis

Indexed keywords

ADALIMUMAB; ARMODAFINIL; CYTOKINE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANXIETY; CLINICAL EVALUATION; COMORBIDITY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FATIGUE; GRANULOMA; HUMAN; HYPOTHYROIDISM; MEDICAL PARAMETERS; MEDICAL RESEARCH; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; REVIEW; SARCOIDOSIS; SLEEP DISORDER; SLEEP PATTERN; TREATMENT RESPONSE;

ANXIETY; DEPRESSION; FATIGUE; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; SARCOIDOSIS;

EID: 84863430744     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00002512     Document Type: Review

References (81)

1. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011; 139: 174-182.
2. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165.
4. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
5. Michielsen HJ, Drent M, Peros-Golubicic T, et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130: 989-994. (Pubitemid 44583726)
6. Wirnsberger RM, de Vries J, Wouters EF, et al. Clinical presentation of sarcoidosis in the Netherlands an epidemiological study. Neth J Med 1998; 53: 53-60. (Pubitemid 28394069)
7. Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-α treatment. Respiration 2010; 80: 212-219.
8. Baydur A, Alavy B, Nawathe A, et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 2011; 5: 156-164.
9. Korenromp IH, Grutters JC, van den Bosch JM, et al. Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue. Brain Behav Immun 2011; 25: 1498-1502.
10. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-634.
11. de Kleijn WP, Drent M, Vermunt JK, et al. Types of fatigue in sarcoidosis patients. J Psychosom Res 2011; 71: 416-422.
12. Sharma OP. Fatigue and sarcoidosis. Eur Respir J 1999; 13: 713-714. (Pubitemid 29234765)
13. Korenromp IH, Heijnen CJ, Vogels OJ, et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011; 140: 441-447.
14. Wirnsberger RM, de Vries J, Breteler MH, et al. Evaluation of quality of life in sarcoidosis patients. Respir Med 1998; 92: 750-756. (Pubitemid 28279449)
15. Drent M, Wirnsberger RM, de Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13: 718-722. (Pubitemid 29234767)
16. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-213. (Pubitemid 47068223)
17. Hinz A, Fleischer M, Brahler E, et al. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011; 33: 462-468.
18. de Kleijn WP, Elfferich MD, De Vries J, et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 92-97.
19. Hoitsma E, De Vries J, van Santen-Hoeufft M, et al. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 33-39. (Pubitemid 36559732)
20. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60: 32-38. (Pubitemid 40101015)
21. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review of the literature. Clin Chest Med 2008; 29: 525-532. (Pubitemid 351778213)
22. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1528-1537. (Pubitemid 47477911)
23. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, et al. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102: 1636-1642.
24. Wirnsberger RM, Drent M, Hekelaar N, et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997; 10: 1450-1455. (Pubitemid 27311054)
25. Michielsen HJ, De Vries J, Drent M, et al. Psychometric qualities of the Fatigue Assessment Scale in Croatian sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 133-138. (Pubitemid 41020020)
26. Michielsen HJ, Peros-Golubicic T, Drent M, et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007; 74: 401-405. (Pubitemid 47093152)
27. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 57-63. (Pubitemid 38533815)
28. De Vries J, Michielsen H, Van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-291. (Pubitemid 39277403)
29. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 127-136. (Pubitemid 38954753)
30. De Vries J, Van Heck GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health 1999; 30: 99-114.
31. Elfferich MD, De Vries J, Drent M. Type D or "distressed" personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 65-71.
32. Drent M, Wirnsberger RM, Breteler MH, et al. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 59-66. (Pubitemid 28174898)
33. Wirnsberger RM, De Vries J, Jansen TL, et al. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. Neth J Med 1999; 54: 86-95. (Pubitemid 29114980)
34. Spruit MA, Thomeer MJ, Gosselink R, et al. Hypogonadism in male outpatients with sarcoidosis. Respir Med 2007; 101: 2502-2510. (Pubitemid 350000964)
35. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133: 1189-1195. (Pubitemid 351685525)
36. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 219-227. (Pubitemid 39472247)
37. de Kleijn WP, De Vries J, Wijnen PA, et al. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-1395.
38. ild care foundation. Questionnaires. www.ildcare.nl/index.php?id5100
39. de Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15: 499-506.
40. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163: 329-334. (Pubitemid 32158507)
41. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007; 29: 147-155.
42. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105: 1917-1924.
43. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49: 1510-1517. (Pubitemid 37011740)
44. Ziegenhagen MW, Rothe ME, Schlaak M, et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003; 21: 407-413. (Pubitemid 36336197)
45. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-1137.
46. Teirstein AS, Machac J, Almeida O, et al. Results of 188 wholebody fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
47. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-1543.
48. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 143-149.
49. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-129.
50. Darko DF, Miller JC, Gallen C, et al. Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor a, and human immunodeficiency virus infection. Proc Natl Acad Sci USA 1995; 92: 12080-12084. (Pubitemid 26014015)
51. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009; 33: 355-366.
52. Hoitsma E, Faber CG, Drent M, et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3: 397-407. (Pubitemid 38789135)
53. Baune BT, Wiede F, Braun A, et al. Cognitive dysfunction in mice deficient for TNF-a and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1056-1064.
54. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008; 5: 2.
55. Alkam T, Nitta A, Mizoguchi H, et al. Restraining tumor necrosis factor-α by thalidomide prevents the amyloid β-induced impairment of recognition memory in mice. Behav Brain Res 2008; 189: 100-106.
56. Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med 1997; 102: 357-364. (Pubitemid 27249102)
57. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1044-1053.
58. Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006; 77: 34-39. (Pubitemid 43022687)
59. Drent M, Verbraecken J, van der Grinten C, et al. Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis. Respiration 2000; 67: 337-340. (Pubitemid 30330432)
60. Verbraecken J, Hoitsma E, van der Grinten CP, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 137-146. (Pubitemid 38954754)
61. Turner GA, Lower EE, Corser BC, et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 61-64. (Pubitemid 27170556)
62. Abad VC, Sarinas PS, Guilleminault C. Sleep and rheumatologic disorders. Sleep Med Rev 2008; 12: 211-228. (Pubitemid 351657735)
63. Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 713-720.
64. Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105: 101-105.
65. Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007; 13: 439-444. (Pubitemid 47472308)
66. Chauffier K, Salliot C, Berenbaum F, et al. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012; 51: 60-68.
67. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204.
68. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 73-77. (Pubitemid 44259213)
69. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 235. (Pubitemid 41668362)
70. Baughman RP, Malhorta A, Surdulescu V, et al. Armodafinil (R-modafinil) for fatigue in sarcoidosis: not just for treating hypersomnulence. Chest 2009; 136: 128s.
71. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 2010; 44: 1098-1103.
72. Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010; 7: CD006704.
73. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009; 38: 650-662.
74. Boulos MI, Murray BJ. Current evaluation and management of excessive daytime sleepiness. Can J Neurol Sci 2010; 37: 167-176.
75. Golicki D, Bala MM, Niewada M, et al. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit 2010; 16: RA177-186.
76. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007; 101: 616-627. (Pubitemid 46196315)
77. Roth T, Rippon GA, Arora S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath 2008; 12: 53-62.
78. Bogan RK. Armodafinil in the treatment of excessive sleepiness. Expert Opin Pharmacother 2010; 11: 993-1002.
79. Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc 2009; 84: 958-972.
80. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
81. White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377: 823-836.